KR100499812B1 - 아목시실린 및 클라불라네이트를 포함하는 약제학적 제형 - Google Patents

아목시실린 및 클라불라네이트를 포함하는 약제학적 제형 Download PDF

Info

Publication number
KR100499812B1
KR100499812B1 KR10-1999-7007362A KR19997007362A KR100499812B1 KR 100499812 B1 KR100499812 B1 KR 100499812B1 KR 19997007362 A KR19997007362 A KR 19997007362A KR 100499812 B1 KR100499812 B1 KR 100499812B1
Authority
KR
South Korea
Prior art keywords
amoxicillin
clavulanate
granules
weight
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1999-7007362A
Other languages
English (en)
Korean (ko)
Other versions
KR20000071076A (ko
Inventor
자키 앙드레 기스타브 마셔
조세 루이스 산로마보르달로
케빈 스톰
Original Assignee
스미스클라인 비참 코포레이션
라보라뜨와르 글락소스미스클라인
스미쓰클라인 비참 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9703101.7A external-priority patent/GB9703101D0/en
Priority claimed from GBGB9703100.9A external-priority patent/GB9703100D0/en
Priority claimed from GBGB9703099.3A external-priority patent/GB9703099D0/en
Application filed by 스미스클라인 비참 코포레이션, 라보라뜨와르 글락소스미스클라인, 스미쓰클라인 비참 에스.에이. filed Critical 스미스클라인 비참 코포레이션
Publication of KR20000071076A publication Critical patent/KR20000071076A/ko
Application granted granted Critical
Publication of KR100499812B1 publication Critical patent/KR100499812B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
KR10-1999-7007362A 1997-02-14 1998-02-10 아목시실린 및 클라불라네이트를 포함하는 약제학적 제형 Expired - Fee Related KR100499812B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9703101.7A GB9703101D0 (en) 1997-02-14 1997-02-14 Formulations
GB9703101.7 1997-02-14
GBGB9703100.9A GB9703100D0 (en) 1997-02-14 1997-02-14 Formulations
GB9703099.3 1997-02-14
GB9703100.9 1997-02-14
GBGB9703099.3A GB9703099D0 (en) 1997-02-14 1997-02-14 Formulations
PCT/EP1998/000811 WO1998035672A1 (en) 1997-02-14 1998-02-10 Pharmaceutical formulations comprising amoxocyllin and clavulanate

Publications (2)

Publication Number Publication Date
KR20000071076A KR20000071076A (ko) 2000-11-25
KR100499812B1 true KR100499812B1 (ko) 2005-07-08

Family

ID=27268719

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1999-7007362A Expired - Fee Related KR100499812B1 (ko) 1997-02-14 1998-02-10 아목시실린 및 클라불라네이트를 포함하는 약제학적 제형

Country Status (25)

Country Link
EP (2) EP1142574A1 (https=)
JP (1) JP2001512451A (https=)
KR (1) KR100499812B1 (https=)
CN (1) CN1194687C (https=)
AP (1) AP1253A (https=)
AT (1) ATE243516T1 (https=)
AU (1) AU728526B2 (https=)
BG (1) BG103664A (https=)
BR (1) BR9807383A (https=)
CA (1) CA2280857A1 (https=)
DE (1) DE69815833T2 (https=)
DZ (1) DZ2420A1 (https=)
EA (1) EA002595B1 (https=)
ES (1) ES2201468T3 (https=)
HK (1) HK1043041A1 (https=)
ID (1) ID23673A (https=)
IL (1) IL131201A (https=)
MA (1) MA24473A1 (https=)
NO (1) NO993887L (https=)
NZ (1) NZ337043A (https=)
OA (1) OA11087A (https=)
PL (1) PL334976A1 (https=)
SK (1) SK110299A3 (https=)
TR (1) TR199901961T2 (https=)
WO (1) WO1998035672A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
TR199800415T1 (en) 1995-09-07 1998-05-21 Smithkline Beecham Corporation Farmas�tik form�lasyon.
GB9815532D0 (en) * 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
AU2869100A (en) * 1999-02-26 2000-09-14 Biovail International Ltd. Storage stable amoxycillin and clavulanate suspension composition
NO329694B1 (no) * 1999-04-13 2010-12-06 Beecham Pharm Pte Ltd Farmasoytisk formulering og anvendelse derav, samt belagt tablett
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
EP1078627B1 (en) * 1999-08-20 2006-08-02 Laboratoire GlaxoSmithKline S.A.S. Pharmaceutical formulation comprising amoxycillin and clavulanate
FR2797588B1 (fr) * 1999-08-20 2003-08-01 Smithkline Beecham Lab Formulation pharmaceutique a base d'amoxycilline et de clavulanate
US6541025B1 (en) * 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6375982B1 (en) * 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
AU2001292185A1 (en) 2000-10-12 2002-04-22 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
AT413983B (de) * 2001-04-12 2006-08-15 Sandoz Ag K-clavulanat in der form eines granulates
AT412344B (de) * 2001-04-12 2005-01-25 Sandoz Ag Hydrophobisierte teilchen von k-clavulanat
WO2003063820A2 (en) * 2002-02-01 2003-08-07 Sandoz Gmbh Demixing-stable granulate
KR20050005437A (ko) * 2002-04-09 2005-01-13 플라멜 테크놀로지스 아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제
AU2003249116A1 (en) * 2002-07-16 2004-02-02 Ranbaxy Laboratories Limited Dispersible tablets for oral administration
MXPA05013433A (es) * 2003-06-16 2006-03-09 Glaxo Group Ltd Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato.
CN1968682A (zh) * 2004-06-18 2007-05-23 株式会社柳韩洋行 包含表面改性的碳酸氢钠的阿莫西林和/或克拉维酸口服分散片组合物
SI21912A (sl) * 2004-12-24 2006-06-30 Lek Farmacevtska Druzba D.D. Stabilne farmacevtske oblike, ki vsebujejo amoksicilin in klavulansko kislino
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
CN100464750C (zh) * 2006-02-23 2009-03-04 珠海联邦制药股份有限公司 一种制备含阿莫西林钠和克拉维酸钾的药物混合物的方法
FI20070521L (fi) 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
FI20080351A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
FI20080352A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi korkean lääkepitoisuuden tabletin valmistamiseksi
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
EP2291233B1 (en) 2008-05-09 2019-09-04 Atacama Labs Oy Method for dry granulation
CN102861015B (zh) * 2011-07-05 2015-07-08 北京乐维生物技术有限公司 一种稳定的阿莫西林克拉维酸钾缓释制剂及其制备工艺
WO2014065769A1 (en) * 2012-10-22 2014-05-01 Bilgiç Mahmut Formulations for oral suspensions comprising antibiotics
WO2015040093A1 (en) * 2013-09-20 2015-03-26 Dsm Sinochem Pharmaceuticals Netherlands B.V. Tablet comprising crospovidone
US9254261B2 (en) * 2014-03-03 2016-02-09 Sandoz Ag Stable quick dissolving dosage form comprising amoxicillin and clavulanic acid
KR102002906B1 (ko) * 2016-10-18 2019-07-23 경동제약 주식회사 셀레콕시브를 포함하는 정제
CN114072493A (zh) 2019-07-05 2022-02-18 葛兰素史密斯克莱知识产权（第2 号）有限公司 棒状链霉菌
CN113274357B (zh) * 2021-05-28 2022-12-27 广州白云山医药集团股份有限公司白云山制药总厂 一种阿莫西林药物及其制备方法
CN114869884A (zh) * 2021-07-30 2022-08-09 江苏恒丰强生物技术有限公司 一种用于猪呼吸道疾病的复方阿莫西林粉及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019227A2 (en) * 1991-05-08 1992-11-12 Laboratorios Beecham Sa Pharmaceutical formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110165A (en) * 1974-04-20 1978-08-29 Beecham Group Limited Process for the production of clavulanic acid
US4140764A (en) * 1974-12-18 1979-02-20 Beecham Group Limited β-Lactamase inhibitors and process for their preparation
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
EP1034784A3 (en) * 1993-01-22 2001-06-27 Smithkline Beecham Plc Pharmaceutical formulations containing clavulanic acid and an antibacterial agent
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
GB9405856D0 (en) * 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DZ1926A1 (fr) * 1994-09-03 2002-02-17 Smithkline Beckman P L C Formulations pharmaceutiques.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019227A2 (en) * 1991-05-08 1992-11-12 Laboratorios Beecham Sa Pharmaceutical formulations

Also Published As

Publication number Publication date
EP0975342A1 (en) 2000-02-02
JP2001512451A (ja) 2001-08-21
MA24473A1 (fr) 1998-10-01
EA002595B1 (ru) 2002-06-27
DE69815833T2 (de) 2004-05-19
IL131201A (en) 2005-06-19
ES2201468T3 (es) 2004-03-16
ATE243516T1 (de) 2003-07-15
SK110299A3 (en) 2000-08-14
EA199900647A1 (ru) 2000-06-26
OA11087A (en) 2003-03-13
NO993887D0 (no) 1999-08-12
CN1194687C (zh) 2005-03-30
AP1253A (en) 2004-03-17
NZ337043A (en) 2001-02-23
CN1251990A (zh) 2000-05-03
AU6719698A (en) 1998-09-08
PL334976A1 (en) 2000-03-27
EP0975342B1 (en) 2003-06-25
NO993887L (no) 1999-08-12
EP1142574A1 (en) 2001-10-10
BG103664A (en) 2000-03-31
CA2280857A1 (en) 1998-08-20
WO1998035672A1 (en) 1998-08-20
TR199901961T2 (xx) 1999-11-22
DE69815833D1 (de) 2003-07-31
AP9901623A0 (en) 1999-09-30
HK1043041A1 (en) 2002-09-06
DZ2420A1 (fr) 2003-01-04
ID23673A (id) 2000-05-11
KR20000071076A (ko) 2000-11-25
IL131201A0 (en) 2001-01-28
BR9807383A (pt) 2000-03-14
AU728526B2 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
KR100499812B1 (ko) 아목시실린 및 클라불라네이트를 포함하는 약제학적 제형
AU737738B2 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
US5211958A (en) Pharmaceutical composition and process for its preparation
AU711441B2 (en) Pharmaceutical formulation
US20030124187A1 (en) Pharmaceutical formulations comprising amoxycillin and clavulanate
US20100016322A1 (en) Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same
CZ237993A3 (en) Tablet medicament form
EA001537B1 (ru) Гранулят для получения быстрораспадающихся и быстрорастворяющихся композиций, содержащих большое количество лекарственного средства
US6080427A (en) Cefadroxil monohydrate tablet formulation
KR20050062514A (ko) 경구 투여용 분산성 정제
US5670170A (en) Pharamaceutical formulation
JPH08208484A (ja) セファクロル含有医薬配合物
EP1173216A1 (en) Pharmaceutical formulations
WO2004014337A2 (en) A process for the preparation of dispersible tablet of cephalexin
HK1003219B (en) Pharmaceutical formulation
HK1003219A1 (en) Pharmaceutical formulation
AU769080B2 (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate
EP2481395A1 (en) Sachet, effervescent tablet and dry syrup of otilonium
MXPA99007517A (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate
TW202510841A (zh) 賦形劑造粒物
WO2022180612A1 (en) Orodispersible formulation of hypolipidemic agent
HUP0001584A2 (hu) Amoxicillint és klavulanátot tartalmazó gyógyászati készítmény
CZ288599A3 (cs) Farmaceutický prostředek
SI9200080A (sl) Farmacevtski sestavki, ki vsebujejo stisnjene granulate zdravila

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20080629

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20080629

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000